Literature DB >> 17064987

Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.

Umberto Gianelli1, Claudia Vener, Paola Rafaniello Raviele, Alessia Moro, Federica Savi, Claudio Annaloro, Francesco Somalvico, Franca Radaelli, Vito Franco, Giorgio Lambertenghi Deliliers.   

Abstract

We reviewed a large series of patients with essential thrombocythemia diagnosed on the basis of the Polycythemia Vera Study Group criteria, and reclassified them by evaluating their major morphologic features and clinical course using the World Health Organization classification. The morphologic review of the bone marrow biopsies of 116 patients (44 males and 72 females; aged 19 - 83 years, median 55 years; median follow-up 121 months) led to 22 cases (19%) being classified as essential thrombocythemia (ET), 24 (21%) as chronic idiopathic myelofibrosis (CIMF)-0, 44 (37%) as CIMF-1, 13 (12%) as CIMF-2, 9 (8%) as latent phase polycythemia vera, and four (3%) as chronic myeloproliferative disorder, unclassifiable. There was a significant difference in the median age of the ET and fibrotic CIMF patients (54.7 +/- 13.55 vs. 59.13 +/- 15.05 years; P = 0.03). Histologic analysis showed that the simultaneous presence of loose clusters of large/giant megakaryocytes and nuclear hyperlobulation was significantly different between the ET and the prefibrotic CIMF (P<0.01) and fibrotic CIMF patients (P<0.01), and that the association of dense clusters of megakaryocytes with maturation defects and bulbous nuclei also distinguished the prefibrotic CIMF (P<0.05) and fibrotic CIMF patients (P<0.001) from those with ET. The association of cellularity, granulocytic proliferation and reticulin fibers was helpful in distinguishing prefibrotic from fibrotic CIMF (P<0.001).

Entities:  

Mesh:

Year:  2006        PMID: 17064987     DOI: 10.1080/10428190600678975

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

1.  Myelofibrotic transformation in essential thrombocythemia.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

Review 2.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

3.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 4.  Advances and challenges in the management of essential thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Ther Adv Hematol       Date:  2015-06

5.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

6.  Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.

Authors:  Young-Uk Cho; Hyun-Sook Chi; Eun-Hye Lee; Seongsoo Jang; Chan-Jeoung Park; Eul-Ju Seo
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

7.  Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Authors:  H Gisslinger; G Jeryczynski; B Gisslinger; A Wölfler; S Burgstaller; V Buxhofer-Ausch; M Schalling; M-T Krauth; A-I Schiefer; C Kornauth; I Simonitsch-Klupp; C Beham-Schmid; L Müllauer; J Thiele
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

8.  Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.

Authors:  Elisa Rumi; Emanuela Boveri; Marta Bellini; Daniela Pietra; Virginia V Ferretti; Emanuela Sant'Antonio; Chiara Cavalloni; Ilaria C Casetti; Elisa Roncoroni; Michele Ciboddo; Pietro Benvenuti; Benedetta Landini; Elena Fugazza; Daniela Troletti; Cesare Astori; Mario Cazzola
Journal:  Oncotarget       Date:  2017-10-06

Review 9.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

Review 10.  Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Authors:  T Barbui; J Thiele; A M Vannucchi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-08-14       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.